disease (ad)

Aducanumab (BIIB037), A selective human immunoglobulin gamma-1 (IgG1) monoclonal antibody, targets the clustered form of amyloid beta (Aβ). Aducanumab shows brain permeability and may be used to treat Alzheimer's disease (AD).

Bapineuzumab, an anti-β-amyloid protein (APP) monoclonal antibody, is utilized in Alzheimer's disease (AD) research [1].

Bepranemab (UCB 0107) is a humanized anti-tau monoclonal antibody of the IgG class for the study of Alzheimer's disease (AD) and tau protein disorders.

Gosuranemab (BMS-986168), a humanized IgG4 anti-tau monoclonal antibody, specifically targets human N-terminal tau residues 15-22. It holds potential for Alzheimer's disease (AD) research [1] [2].

Lecanemab (BAN-2401) is an IgG1 monoclonal antibody targeting soluble aggregated β-amyloid (Abeta) with activity against oligomers, protofibrils, and insoluble protofibrils, and may be useful in the study of Alzheimer's disease (AD)-induced mild cognitive impairment and mild AD dementia.

Vanutide cridificar (ACC-001) is an aminoterminal Aβ1-7 peptide conjugate used in Alzheimer's disease (AD) research [1].